GlassScriptPhysician profile
Jared Joshua Carbone
NPI 1164810610
$6,895.36
in general payments reported to CMS, 2019-2025
29 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,072 · 2022: $1,433 · 2023: $2,127 · 2024: $43.45 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,625.96 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $577.52 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $556.07 | 2021-2023 | Rexulti, Nuedexta |
| Sunovion Pharmaceuticals INC. | $439.38 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $417.43 | 2021-2023 | Austedo, Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $399.12 | 2021-2025 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.64 | 2021-2023 | |
| Alkermes, INC. | $340.33 | 2021-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $324.54 | 2022-2025 | Auvelity |
| Lundbeck LLC | $302.16 | 2021-2023 | Rexulti |
| Bausch Health US, LLC | $239.23 | 2021-2023 | Aplenzin |
| Corium, LLC | $194.20 | 2021-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $156.13 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $147.65 | 2023-2025 | Qelbree, Qelbree |
| Avanir Pharmaceuticals, INC. | $139.25 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103.45 | 2022 | |
| Neos Therapeutics, LP | $88.40 | 2021-2023 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $74.09 | 2021-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $72.93 | 2021-2023 | Spravato |
| Tris Pharma INC | $70.64 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $65.09 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $57.26 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $35.73 | 2021 | |
| Idorsia Pharmaceuticals US INC | $32.78 | 2023 | Quviviq |
| Gilead Sciences, INC. | $14.06 | 2021 | |
| Acadia Pharmaceuticals INC | $14.01 | 2021 | |
| Adlon Therapeutics L.P. | $12.76 | 2021 | |
| Aytu Biopharma, INC. | $12.72 | 2021 | |
| Allergan, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Carbone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.